INIVATA LIMITED

Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers

Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.

Accounting basis

FRS 102

Reporting scope

Standalone (parent only)

Auditor

Deloitte LLP

Audit opinion

Unqualified (clean)

Going concern

Affirmed

“The Company experienced a comprehensive loss of $37,223,040 (2023: $25,860,814) and has net liabilities of $84,939,048 (2023: $47,881,589). The Company is dependent on continued financial support from NeoGenomics which the Directors will receive for a period of at least 12 months from the date of this reporting being approved and signed as stated in the letter of support between NeoGenomics and Inivata Limited. The Directors have satisfied themselves that NeoGenomics has sufficient resources to do so and therefore consider it to be appropriate to continue preparing the financial statements on a going concern basis.”

Significant events

• “In September 2023, the Company began performing Fluorescence In-Situ Hybridization ("FISH"), Flow cytometry ("FLOW"), and Immunohistochemistry ("IHC") testing services for the parent's pharmaceutical customers.”
• “On June 18, 2021, NeoGenomics Laboratories, Inc. ("NeoGenomics") acquired 100% of the equity interests in the Company.”
• “In 2024, development efforts primarily focused on enhancing and developing minimal residual disease tests, advancing liquid biopsy assays, and improving molecular profiling methodologies. The Company validated and launched PanTracer LBx, which is a large panel liquid biopsy test that delivers comprehensive, clinically actionable insights from a blood sample.”
• “A competitor filed a complaint for patent infringement against Inivata Limited in early January 2021.”

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

Filings

6

last 12 months

Capital events

1

last 24 months

Officers appointed

2

last 12 months

Officers resigned

1

last 12 months

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.

• Turnover

  -21.1%

  £4,994,997 → £3,942,492

• Cash

  -68.1%

  £1,427,474 → £455,365

• Net assets

  -77.4%

  -£35,494,136 → -£62,964,454

• Employees

  -1.5%

  68 → 67

• Operating profit

  -46.3%

  -£18,601,653 → -£27,219,971

• Profit before tax

  -49.5%

  -£18,247,790 → -£27,288,263

• Wages

  +7%

  £4,436,064 → £4,748,294

Each % is (latest − prior) ÷ |prior| for the line item as filed. The comparison is only shown when the latest and prior accounts cover broadly equal-length periods — short or long stubs (typical around incorporation or a year-end change) are suppressed rather than misrepresented. Lines a company doesn't report are omitted. About these numbers